^
Association details:
| Biomarker: | BRCA2 A902fs*2 |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | abiraterone acetate (CYP17A1 inhibitor) + Biolen (bicalutamide implant) (Androgen receptor antagonist) + Prosenze (leuprorelin depot) (GnRH stimulant) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Effect of cisplatin on metastatic castration-resistant prostate cancer with BRCA2 mutation: A case report
Published date:
05/17/2021
Excerpt:
A 37-year old man with Pca...Bicalutamide and salvage radiation therapy (SRT) for the prostatic fossa (66 Gy) were introduced. Twenty-five months later, the PSA had decreased...then gradually rose to 11.0 ng/ml despite the addition of leuprorelin acetate followed by abiraterone...After the disease progressed while the patient underwent taxane-based chemotherapy, we performed a genetic test by FoundationONE CDx...Genetic testing revealed a frameshift mutation with a stop codon two positions further in the BRCA2 (pA902fs*2)...
DOI:
10.1016/j.eucr.2021.101712
Test:
